Activation of HCAR2 by niacin: benefits beyond lipid lowering

2019 ◽  
Vol 20 (16) ◽  
pp. 1143-1150
Author(s):  
Sony Tuteja
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Nicotinic Acid ◽  
Immune Cells ◽  
Potential Role ◽  
Metabolic Diseases ◽  
The Body ◽  
Lipid Lowering ◽  
Lipid Lowering Agent

Niacin (nicotinic acid) is a potent lipid-lowering agent that has been used for prevention of coronary heart disease. Niacin activates the HCAR2 receptor found on adipocytes, macrophages and various immune cells throughout the body. Activation of the HCAR2 receptor by niacin results in beneficial anti-inflammatory effects that are independent of lipid lowering. This review summarizes the use of niacin in treatment of dyslipidemia, the pharmacogenetics of niacin response and the potential role of HCAR2 signaling in the treatment of a variety of inflammatory and metabolic diseases.

Effects of Bezafibrate on Low HDL-Cholesterol in Patients with Ischaemic Cerebrovascular Disease: A Pilot Study

1981 ◽  
Vol 9 (5) ◽  
pp. 319-323 ◽  
Author(s):  
L Noring ◽  
K G Kjellin ◽  
H Ledermann
Keyword(s):  
Heart Disease ◽  
Pilot Study ◽  
Cerebrovascular Disease ◽  
Hdl Cholesterol ◽  
Lipid Lowering ◽  
Ischaemic Cerebrovascular Disease ◽  
Low Hdl ◽  
Preliminary Study ◽  
Lipid Lowering Agent

Bezafibrate is a new lipid-lowering agent that quite consistently increases low HDL-cholesterol values in hyperlipoproteinaemic patients. The possible role of HDL-cholesterol as an anti-atherogenic factor has been frequently discussed, mainly in patients with ischaemic heart disease but recently also in ischaemic cerebrovascular disease (ICD). This is the first pilot study in six selected patients suffering from ICD who had at the same time low HDL-cholesterol values (< = 1.1 mmol/l) with otherwise normal lipids. After a wash-out period of 2 months duration these patients were treated with 200 mg bezafibrate t.i.d. for 2 months. They were then followed up for another 8 months. Bezafibrate therapy increased HDL-cholesterol (range 45–130%). Eight months after cessation of therapy five patients have returned to pathologically low HDL-levels and the sixth patient also has a relatively low value of 1.2 mmol/l. This small preliminary study cannot, however, provide evidence about the possible beneficial role of increasing HDL-cholesterol in patients with ICD. Further investigations are therefore in progress.

Modern ideas about the role of hyperuricemia in the pathogenesis of coronary heart disease

2018 ◽  
Vol 2 (1) ◽  
pp. 47-54
Author(s):  
Eleonora TASHKENBAEVA ◽  
◽  
Dilshod TOGAEV ◽  
Farzona KADIROVA ◽  
Shukhrat ZIYADULLAEV ◽  
...  
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease
Sign in / Sign up

Export Citation Format

Share Document